Richard Tanner

Residual inflammatory & cholesterol risk after PCI - 15,494 patients on statin tx - 40% with elevated hsCRP - hsCRP >2mg/L independently associated with MACE @ 1 yr - LDL >70mg/dL not associated with MACE @ 1 yr - Difference in MACE driven by all-cause mortality & spontaneous MI

In this editorial, Prof. Sabaté comments on 3-year outcomes from Tanner et al. on intracoronary brachytherapy for multilayer DES ISR. Despite limitations, the data reintroduce a technique once considered obsolete. ow.ly/Zziy50VzwlH

@MountSinaiHeart @EuroInterventio

Does intravascular brachytherapy (IVBT) still have a role in treating in-stent restenosis (ISR)? Multilayer ISR may be a niche indication for this metal free strategy

➡️The considerable psychological impact of heart disease on patients and their families. 🧠👇

Structural Heart Disease fellowship @MountSinaiHeart complete! Excellent teaching & hands-on experience with MitraClip & TriClip. My sincere thanks to the entire Structural Heart team! @DoctorKini @GilbertTangMD @ParasuramMD @KHERA_MD @LucySafi @georgedangas @SaminSharmaMD

👏🏼🎉New class of @MountSinaiHeart trained structural ❤️interventionalists + imagers. Ready to help pts from around the 🌎! Super proud! @sratanapo @RichCardioMD @RSamtaniMD @PassanitiGiulia @prandi_fr @NanaToyodaMD @DoctorKini @KHERA_MD @ParasuramMD @LucySafi @georgedangas

With shared decision-making, patients sometimes prefer PCI over the recommended CABG. @DrAnoop_Koshy @GreggWStone @DoctorKini and colleagues investigate the outcomes of such decisions in complex coronary cases. #AHAJournals @MountSinaiHeart ahajrnls.org/3KQj00T

Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the AHA Risk stratified by drug class 👇

Delighted to contribute to an expert panel discussion on the lifetime management of aortic stenosis this morning at #NYValves2024

Novel publ in JAHA from our group at Mt Sinai. 3687 pts with MVD and SS >22. Documents for the first time (to my knowledge) worse outcomes (including death) after PCI in pts eligible and recommended for CABG who refused, even after adjustment for SS and other covariates.

Watch First LIVE Case in the World of TF-TAVR with the Novel 26mm Evolut FX+ - Tomorrow at 9am EDT ccclivecases.org/live-webcast/ #cardiotwitter #cardiox #cardiology #structuralheart #TAVR #SAVR

Grand rounds @MountSinaiHeart with expert panelists Dr. Fuster, Dr Bhatt, Dr Adams, Dr Kini, Dr Lerakis moderated by Dr Stone discussing MV disease. Doesn’t really get better than that! @DLBHATTMD @DoctorKini @GreggWStone

Proud to be @MountSinaiHeart ❤️team FIRST commercial #TriClip G4 T-TEER to Rx primary TR & #2 overall in US. Large anterior prolapse Quadricuspid TV: 5➡️1+ TR w/ 1 XTW. ⬆️RV flow, BP, ⬇️RAP. Only commissural jet left. No pacer, no AC needed home next day. Big win for our pts!

Out now in @JACCJournals, our analysis on the role of inflammation in risk prediction among HBR patients undergoing PCI, led by @manishvinayak 👉 ⬆️ hsCRP is associated with high ischemic but not bleeding events 👉 measuring hsCRP may help guide antiplatelet tx in HBR patients

@leoneppmd @azeemlatib @duanepinto @georgedangas @HeartOTXHeartMD @SebLudwig1 @Ortega_Paz @OhnoTuri @crfheart @SVRaoMD @rwyeh @RadialFirstBot @Drroxmehran @mauro_gitto @AngeloOliva3 @GreggWStone Great work Pier!

@azeemlatib @duanepinto @georgedangas @HeartOTXHeartMD @SebLudwig1 @Ortega_Paz @OhnoTuri @crfheart @SVRaoMD @rwyeh @RadialFirstBot @Drroxmehran @mauro_gitto @AngeloOliva3 @GreggWStone

Amazing redo #TAVR live case #SHA2024 @MBalghith @ccclivecases @MountSinaiNYC @MountSinaiHeart @IcahnMountSinai by @DoctorKini @KHERA_MD & our ❤️team of 23S3U Resilia in 29 Evolut for severe PVL. 👏🏼 @bapat_savrtavr @Miho_Fukui_ for the analysis! @LucySafi @Asaadakbarkhan

Huge milestone @MountSinaiHeart @MountSinaiNYC @IcahnMountSinai as we 📈>💯 #MitraClips #Mitral #TEER in 2023. Congrats our A++ ❤️team of structural ❤️cardiologists, surgeons & imagers! @DoctorKini @DrSaminKSharma @DrDavidHAdams @DrStamLerakis @LucySafi @KHERA_MD @ParasuramMD

Great #AHA23 so far: @AHA_Research 🥸8 Trials: 8 take aways below Read the read👇👇 1/ATRESIA: Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.